These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29901215)

  • 21. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?
    Rosenson RS
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):777-82. PubMed ID: 26966281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
    Khera AV; Rader DJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):195-201. PubMed ID: 20211435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CETP Inhibition in CVD Prevention: an Actual Appraisal.
    Di Bartolo B; Takata K; Duong M; Nicholls SJ
    Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel concepts in HDL pharmacology.
    Remaley AT; Norata GD; Catapano AL
    Cardiovasc Res; 2014 Aug; 103(3):423-8. PubMed ID: 24951539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.
    Rashid S; Sniderman A; Melone M; Brown PE; Otvos JD; Mente A; Schulze K; McQueen MJ; Anand SS; Yusuf S
    Eur J Prev Cardiol; 2015 Apr; 22(4):468-77. PubMed ID: 24659026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of lipid-modifying therapy with risk of obstructive sleep apnea: A drug-target mendelian randomization study.
    Zou J; Qi S; Sun X; Zhang Y; Wang Y; Li Y; Zhao ZH; Lei D
    Toxicol Appl Pharmacol; 2024 Apr; 485():116909. PubMed ID: 38521370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.
    Zhang H; de Aguiar Vallim TQ; Martel C;
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):e56-61. PubMed ID: 27335468
    [No Abstract]   [Full Text] [Related]  

  • 31. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
    Athyros VG; Kakafika A; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Investig Drugs; 2008 Apr; 17(4):445-9. PubMed ID: 18363511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects.
    Qin Y; Xia M; Ma J; Hao Y; Liu J; Mou H; Cao L; Ling W
    Am J Clin Nutr; 2009 Sep; 90(3):485-92. PubMed ID: 19640950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Will CETP inhibition survive the demise of torcetrapib?
    Olsson AG
    Curr Atheroscler Rep; 2008 Apr; 10(2):97-9. PubMed ID: 18417061
    [No Abstract]   [Full Text] [Related]  

  • 37. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
    Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Would Janus' view on HDL be useful?
    Kasko M; Kasko V; Oravec S
    Bratisl Lek Listy; 2018; 119(4):245-248. PubMed ID: 29663823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.